One-Stop Canine CAR-T Therapy Development Services

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

With advanced technology platforms and professional technical teams, Creative Biolabs is dedicated to providing one-stop canine CAR-T therapy development services to facilitate your project's success.

Advantages of Canine as a Disease Model for CAR-T Research

The canine genome shares greater homology with the human genome compared to other mammals.
Canine and human beings are susceptible to many diseases, especially complex diseases such as cancer.
The incidence rate of cancer occurs spontaneously in canine at least comparable to human cancer, and often closely resembles the characteristics of human tumors.
Humans and canines are subject to a lot of the same environmental factors that may influence disease occurrence and progression.

Our One-Stop Canine CAR-T Therapy Development Service

Creative Biolabs provides one-stop customized, high-quality CAR-T therapy development services to support customers' projects worldwide. For canine CAR-T development, our services range from early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

CAR Design & Construction CAR-T Gene Packaging & Delivery Canine CAR-T Engineering Service Canine CAR-T Development Service for Hematologic Malignancies Canine CAR-T Development Service for Solid Tumor Canine CAR-T Cell Characterization Service

Fig.1 The flowchart of canine CAR-T development services. (Creative Biolabs)

Features & Benefits

A Full Range of CAR Design & Construction to Empower Canine CAR-T Therapy Development Service

Creative Biolabs have established many CAR Design & Construction platforms to empower canine CAR-T engineering, the following constructions you can choose from, including but not limited to:

CAR Design & Construction
First Generation of CARs Design	Second Generation of CARs Design	Third Generation of CARs Design	Smarter™ Technology for 4th Generation CAR
Physiological CAR Construction Service	Universal CAR Construction Service	Smarter™ Armored CAR Construction Service	Smarter™ Dual CAR Construction Service

Optimized CAR-T Gene Packaging & Delivery Approach to Facilitate Canine CAR-T Therapy Development Service

We offer non-viral systems delivery approaches such as IVT mRNA, and various viral-based vector systems delivery approaches such as lentivirus, and retrovirus vector to assist canine CAR-T development. Meanwhile, we will optimize the gene packaging & delivery system to meet clients' needs.

Fig.2 CAR-T cell transfection approaches. (Creative Biolabs)

Comprehensive Functional Assessment for Canine CAR-T Therapy Development Service

Based on our years of rich experience in the field of CAR-T research, Creative Biolabs has the confidence and ability to provide high-quality canine CAR-T development services. We have established comprehensive in-vitro and in-vivo function assessments to speed up clients' projects.

In Vivo Function Assessment
In Vitro Function Assessment
CAR Expression Test	CellRapeutics™ Cytokine Release Test	CellRapeutics™ Proliferation Test
Single Cell Analysis for CAR-T Cell	T Cell-Mediated Tumor Cell Lysis Assay	CellRapeutics™ Multiplex Cytokine and Chemokine Assay
Efficacy Test of CAR-T	Viability and Bio-distribution Study of CAR-T	Toxicity Evaluation of CAR-T

Published Data

Here are several literary works related to canine CAR-T development.

1. Establishing the CD20-targeting, 2^nd generation canine CARTs for functional evaluation.

Fig.3 Design and function of cCD20-28-ζcanine CAR-T cells. (Panjwani, et al., 2020)	Fig.4 Design and function of cCD20-BB-ζ canine CAR-T cells. (Panjwani, et al., 2020)
2. Establishing the HER2-targeting canine CARTs for solid tumor treatment.

Fig.5 Cytotoxicity assays using canine HER2-CAR T cells with HER2-positive target cells. (Mata, et al., 2014)

For more detailed information about canine CAR-T therapy development services, please feel free to contact us for a tailored solution for you.

References

Panjwani, M.K.; et al. Establishing a model system for evaluating CAR-T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. Oncoimmunology. 2020, 9(1), p.1676615.
Mata, M.; et al. Towards immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. Journal of immunotherapy (Hagerstown, Md.: 1997). 2014, 37(8):407.